Opportunities and challenges from ICH Q2 (2) and Q14 for the analytical lifecycle

This summary accompanies a recent expert forum discussion organised by BioQC. We appreciate the panellists’ time and expertise. The views expressed by the panellists are their personal interpretations and do not represent the positions of their respective organisations.

This panel discussion explored analytical method validation and lifecycle management perspectives through the lens of the newly updated ICH Q2(R2) and ICH Q14 guidelines.

Enhanced Approach and Analytical Quality by Design: Continuity Rather Than Revolution

The opening discussion addressed whether the enhanced approach introduced by ICH Q14, grounded in analytical quality by design (AQbD), represents a meaningful departure from existing scientific practice.

Panellists broadly agreed that for experienced analytical scientists already employing structured, scientifically driven development strategies, the enhanced approach formalises what many are effectively already doing rather than mandating fundamentally new activities.

A common misconception identified was the conflation of AQbD with design of experiments. Design of experiments is one tool within the AQbD framework, deployed when knowledge generation requires it. Where existing scientific understanding is sufficient, additional experimental work is not mandated. Well-structured, risk-driven method development constitutes AQbD in practice, irrespective of whether practitioners apply that terminology. Good science and systematic thinking represent the substance of the approach; terminology serves communication rather than scientific rigour.

From the quality control perspective, the principle that development and validation activities should not be treated as tick-box exercises was emphasised. Gaining knowledge throughout method development and validation ensures that data collected remain useful across the method lifecycle.

When performance issues arise, drift occurs, or changes become necessary, a comprehensive knowledge base accumulated during development can streamline responses and support method improvements without starting from the beginning.

Confidence Intervals and Validation Study Design: Rethinking the Statistical Framework

The introduction of confidence interval requirements for accuracy and precision within the updated guidelines presents practical challenges for validation study design, particularly in quality control settings. Panellists highlighted that the non-retrospective nature of these requirements, confirmed within ICH training materials rather than the guideline text itself, provides important relief.

Legacy methods validated against existing criteria need not be revalidated under the new framework. New methods and modified methods, however, require the updated approach from the outset.

For quality control environments managing established methods, the new confidence interval requirements can significantly increase the number of experimental sessions required to achieve adequate statistical power. This cost consideration prompted evaluation of alternative approaches. A total error methodology, incorporating prediction intervals rather than separate assessment of accuracy and precision, was described as less resource-intensive in many situations whilst remaining fully compatible with the requirements introduced in ICH Q2(R2). Importantly, this approach aligns more coherently with how acceptance criteria are constructed relative to product specifications, particularly in complex biopharmaceutical contexts such as vaccines.

Panellists cautioned against setting dual acceptance criteria across both the separate and combined approaches simultaneously, recommending instead that teams commit to a single decision-making framework.

Bringing total error information for informational purposes alongside a primary separate assessment, or vice versa, risks creating situations where the method may satisfy one set of criteria whilst appearing to fall short against another, generating unnecessary ambiguity. Clarity in decision-making frameworks is essential for regulatory defensibility and operational efficiency.

Precision data retains particular importance even where the total error approach is adopted as the primary decision framework. Precision estimates underpin lifecycle strategies, deviation investigations, and change management activities.

The guideline continues to require accuracy and precision to be reported separately, without necessarily demanding separate acceptance criteria when a total error approach is the chosen decision basis.

Continue Reading…

Register using the download form below to read the full summary (PDF) and meet the panel.

Would you like to read more summaries?